<DOC>
	<DOCNO>NCT01345084</DOCNO>
	<brief_summary>Primary : compare overall survival define time elapse randomization date death due cause , treatment group . Secondary : compare progression-free survival , incidence locoregional failure , site first recurrence/progression , objective response rate assessment , quality life assessment incidence adverse event .</brief_summary>
	<brief_title>Study Comparing Radiation Therapy Chemotherapy With Without Nimotuzumab</brief_title>
	<detailed_description>This phase III , superiority , national , open-label , randomize , two-arm study . Patients ' enrollment perform approval competent regulatory authority last 12 month . All patient take part study must sign informed consent . The patient stage III IV , unresectable head neck SCC , performance status 0 1 . Randomization treatment assignment perform company specifically contract purpose per research site disease stage , 1:1</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion Criteria Aged 18 75 year old ; Histological cytological confirmation SCC oral cavity , oropharynx , hypopharynx , larynx ; Stages III IV disease Unresectability accord responsible surgeon medical staff 's opinion ; Performance status 0 1 Present indication radiation therapy chemotherapy treatment cisplatin ; Adequate hepatic , renal medullar function , indicate : Life expectancy 6 month . Exclusion Criteria Presence nasopharyngeal , paranasal sinus , salivary gland carcinoma ; Presence know distant metastasis ; Presence active neoplasm history tumor diagnose last 5 year Patients inability eat normally , gastric enteral tube possible least 2 week enrollment study ; Previous treatment chemotherapy , radiation therapy , EGFR inhibitor pharmacological class ; Presence serious comorbidity , investigator 's opinion , put patient risk jeopardize protocol compliance ; Active know seropositivity HIV , hepatitis B C Presence significant neurological psychiatric disease , per investigator 's judgment ; Hypersensitivity allergy study treatment ; Presence uncontrolled hypercalcemia ; Pregnancy breastfeeding ; Female patient childbearing potential wish become pregnant unwilling , well partner , use appropriate contraceptive method throughout study period ; Participation clinical trial last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>